Tada,

it is always hard to know in such situations what true value is.  But let's pick up your suggestion that the cognitive side alone could be worth upto $40/share.  

For this to be the case, you have to start with basic questions...for example, would kidney disease and dementia be considered "orphan" diseases? What about Heart Disease?  

I realize that "orphan disease status" is meant for those affecting less than 200,000 people in the US.  But broadly speaking, in spirit, it should also include diseases that don't have any cure today.  Won't kidney disease be one?  Dementia?  Even CVD with over 70% unmet needs should really qualify as an "orphan" disease...we are no where close to even curing CVD.

If the data on Nov 16 validates all our optimism about Apabetalone, won't the FDA be inclined to fast track our drug with some conditions about future tests?  

And then we get down to which company buys out RVX.